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Abstract: Polyglutamine (PolyQ) diseases are a group of neurodegenerative disorders caused by the
expansion of cytosine–adenine–guanine (CAG) trinucleotide repeats in the coding region of specific genes.
This leads to the production of pathogenic proteins containing critically expanded tracts of glutamines.
Although polyQ diseases are individually rare, the fact that these nine diseases are irreversibly progressive
over 10 to 30 years, severely impairing and ultimately fatal, usually implicating the full-time patient
support by a caregiver for long time periods, makes their economic and social impact quite significant.
This has led several researchers worldwide to investigate the pathogenic mechanism(s) and therapeutic
strategies for polyQ diseases. Although research in the field has grown notably in the last decades, we
are still far from having an effective treatment to offer patients, and the decision of which compounds
should be translated to the clinics may be very challenging. In this review, we provide a comprehensive
and critical overview of the most recent drug discovery efforts in the field of polyQ diseases, including
the most relevant findings emerging from two different types of approaches—hypothesis-based candidate
molecule testing and hypothesis-free unbiased drug screenings. We hereby summarize and reflect on the
preclinical studies as well as all the clinical trials performed to date, aiming to provide a useful framework
for increasingly successful future drug discovery and development efforts. C© 2016 Wiley Periodicals, Inc.
Med. Res. Rev., 00, No. 0, 1–47, 2016
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1. INTRODUCTION
Polyglutamine (PolyQ) diseases are a large group of inherited neurodegenerative disorders
characterized by the pathological expansion of cytosine–adenine–guanine (CAG) repeats in
the coding sequences of distinct genes leading to the production of mutant proteins bear-
ing expanded polyQ tracts. PolyQ diseases include Machado–Joseph disease (MJD/SCA3),1
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Huntington’s disease (HD),2 spinal and bulbar muscular atrophy (SBMA),3 dentatorubral-
pallidoluysian atrophy (DRPLA),4,5 and other spinocerebellar ataxias (SCA1, SCA2, SCA7,
and SCA176–12; see Table I for a summary of disease features). The frequency of polyQ diseases
averages 1–10:100,00013; of these, HD andMJD/SCA3 are the most common worldwide.14 All
are progressive, ultimately fatal disorders that typically begin in midlife and progress over 10 to
30 years. PolyQ diseases are inherited in an autosomal dominant manner, with the exception
of SBMA, which is X-linked, and they only manifest when the glutamine expansions exceed a
certain threshold.15 Above the pathogenic threshold, the CAG tracts are usually unstable across
generations, and they can expand or contract in a variably manner, particularly depending on
the sex of the transmitting parent.16 This intergenerational instability causes, on average, an
increase in repeat length, leading to earlier age-at-onset and increased severity of the symptoms
in the successive generations, a phenomenon known as anticipation.17–19 In addition to inter-
generational instability, tissue-specificmosaicism has been observed in polyQ diseases, resulting
in cell populations carrying different CAG repeat lengths, within or between tissues.20–24 This
CAG repeat instability underlies some features of polyQ disorders and may also contribute to
their pathogenic mechanism.25–27
At the molecular level, the disease-causing proteins are ubiquitously expressed, in the
nervous system and peripheral tissues; however, each polyQ disease is characterized by the
loss of specific neuronal populations, resulting in typical patterns of neurodegeneration and
characteristic clinical symptoms.28 A common feature of all polyQdisorders is the accumulation
of aggregated forms of the mutant protein, in the cytoplasm and mostly in the nucleus of the
neuronal cells, ultimately forming neuronal intranuclear inclusions (NIIs), which are found
in patient brains and transgenic models of the disorders.29,30 These inclusions are a common
hallmark of all these diseases; however, it is still controversial if they are pathogenic or not.31–34
Learning from early investigations in Alzheimer’s disease (AD) and Parkinson’s disease (PD)
studies (reviewed in 35), several studies have explored which type of structure formed by the
expanded polyQ is responsible for the disease (reviewed in 36 and discussed in Section 2.1.3). On
the one hand, in the initial steps of aggregation, some of the monomeric species that transform
into oligomers and protofibrils/fibrils may be direct intermediates for end-stage aggregate
formation, while others may not be,37 and it is very important to define each of these groups.
On the other hand, the intermediate species along the aggregation pathway may constitute the
most toxic insult to the cell or, at least, have a considerable contribution for pathogenesis. In
fact, both in AD and PD, current research indicates that oligomeric forms are probably the
key pathogenic elements (reviewed in 35): large inclusions are increasingly suggested not to be
so highly toxic,38,39 whereas smaller Aβ and α-synuclein aggregates and intermediate species
such as the oligomers are thought to be the toxic species.40,41 Although this is less clearly
defined for polyQ diseases and the exact role of polyQ aggregation has been widely discussed,
one idea that seems consensual is that (like in AD) cleaved versions of the mutant proteins
are more toxic than their full-length counterparts, that is, proteolytic cleavage of the original
proteins leads to the formation of fragments that contain the polyQ tract, which are more
prone to aggregation, and seem to constitute a more toxic insult to the cell. This is known as
the toxic fragment hypothesis, and the presence of such fragments was shown in several polyQ
diseases.42–51
The theory that a toxic structure of the expanded polyQ causes the disease explains its
length dependence (specific for each polyQ disease, but within very similar thresholds), and im-
plies a common pathogenic mechanism in these diseases. Although this hypothesized common
mechanism is not sufficient to explain the selective toxicity pattern of each of these causative
proteins, which leads to the slightly different neuropathologic affection and clinical manifesta-
tions of each disease,52 its clarification is expected to lead to therapeutic approaches that could
be of use for many of these diseases.
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Other hypotheses have been put forward for polyQpathogenesis,mainly the evidence for the
cell-to-cell propagation of the pathogenic proteins that form the hallmark lesions of these neu-
rodegenerative disorders.53 In this hypothesis, the protein aggregates can in some cases become
infectious and act similarly to prion disorders. The majority of the studies were performed
in HD and suggested that aggregates can replicate, like prions, being able to cross cellular
membranes and “infect” neighbor cells, thus contributing to the disease progression.54–56 Sev-
eral studies have addressed the underlying mechanisms of cell-to-cell aggregate transmission,
release, and uptake.53,57,58
In these diseases, neurons are more frequently affected because they are probably more
sensitive to mutant proteins than other cell types and, since they do not divide, mutant polyQ
proteins more quickly accumulate in these cells. Clearance of misfolded and mutant proteins
is mostly accomplished by the Ubiquitin Proteasome System (UPS) and even more so by
autophagy, processes of high relevance in neurons and whose activities appear to decrease
during the course of the disease.59–63 Nevertheless, mutant proteins are generally ubiquitously
expressed throughout the body and affected peripheral cells might also contribute to the disease
process.64,65 Several studies, mostly in HD, have been carried out to unravel the contribution
of peripheral cells to the disease,66–71 but this still needs to be further assessed, and efforts are
still lacking to unravel whether these changes are primarily caused by the expression of mutant
polyQ proteins in peripheral tissues or are secondary effects of nervous system dysfunction.
Despite the ubiquitous expression of polyQ-proteins, cell-specific neurodegeneration does
exist in this group of diseases. The consistent loss of these neuronal populations has been
proposed to result from the differential vulnerability of these cells to the toxic gain of function
associated with polyQ expansion. As an example, the vulnerability of themedium spiny neurons
(MSN) in the striatum and the pyramidal neurons in the cortex of HD patients has been related
to their morphology, neurotransmitter content, and electrophysiological properties (reviewed in
72). The specific interactions of a given polyQ protein with other tissue- or cell-specific proteins
could also contribute to explain the specificity of neuronal death. For example, in SCA7 it was
demonstrated that retinal degeneration could be associatedwith an altered function of cone-rod
homeobox proteinCRX,73 whereas inHD the striatum-enriched huntingtin interactorRhes has
been shown to be key for the selective toxicity of this polyQ protein.74–78 An understanding of
the interactions between polyQ-proteins and cell type-specific partners and cellular featuresmay
provide a novel conceptual framework for the development of effective therapeutic strategies
in polyQ disorders.
2. THERAPEUTIC STRATEGIES FOR POLYQ DISEASES
Despite great progress in elucidating the pathogenic mechanisms underlying polyQ diseases,
an effective treatment is still lacking. The current strategies toward discovery and development
of therapies for these diseases can be divided according to the model of choice of molecules
to be tested, in candidate-based (or hypothesis-based) studies and unbiased (hypothesis-free)
screenings. The most common are those based on molecules with known properties, targeting
specific aspects of the hypothesized pathological mechanisms, which (see Fig. 1) can further
be divided in two categories: (i) those targeting the expression, processing, or conformation of
the causative polyQ protein; (ii) those preventing the toxic effects of the polyQ protein, such
as mitochondrial dysfunction and oxidative stress, transcriptional dysregulation, UPS and au-
tophagy impairment, excitotoxicity, and/or activation of cell death pathways (see Fig. 2 for
a summary of pathogenic mechanisms and current candidate-based therapeutic approaches);
and, lastly, (iii) those providing a more general neuroprotection.85 On the other hand, unbi-
ased drug screenings are gaining relevance mostly through the analysis of large libraries of
Medicinal Research Reviews DOI 10.1002/med
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Figure 1. Workflow of drug discovery strategies for polyQ diseases considering the selection of molecules to
test (hypothesis-based or hypothesis-free/unbiased) and the level of mechanistic targeting (the polyQ proteins
themselves or the downstream cellular effects). Unbiased screenings can be based on different read-outs, such
as aggregation or toxicity, among others, used to measure efficacy of the compounds.
Figure 2. Pathogenic mechanisms of polyQ diseases and current hypothesis-based therapeutic approaches.
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well-known or new compounds with high-throughput methodologies. These approaches of-
ten reveal interesting disease-modifying agents, contributing not only to define novel elements
within mechanisms of the disease, but also, particularly in the case of repurposing screens,
allowing for a direct pathway to therapy.
Given that neurodegenerative disorders sharemany features, it is not surprising that the field
PolyQ diseases benefit from the knowledge accumulated in other (significantly more common)
diseases, not only in terms of their pathogenic mechanisms but also regarding therapeutic
approaches. Several studies in AD, PD, or amyotrophic lateral sclerosis (ALS) are in fact used
to direct the therapeutic strategies for PolyQ diseases, as referred along this review. The reverse
should also not be discouraged, since recent findings in PolyQ diseases may contribute for a
deeper knowledge on the remaining neurodegenerative diseases, concerning both mechanisms
and therapeutics.
In this review, we will outline recent efforts in drug discovery and development for polyQ
diseases, including both types of strategies. We will start with a summary of preclinical studies
and then move to the clinical trials performed to date in this group of disorders.
A. Candidate-Based Approaches
1. Gene Silencing Through RNA Interference and microRNAs
The most straightforward therapeutic approach for polyQ diseases may be to decrease the
expression levels of themutant protein, and consequently prevent all the downstreamdeleterious
events. Downregulation of the expression of the abnormal gene(s) was shown to be an effective
strategy to halt disease progression in conditional tetracycline-regulated mouse and rat models
of HD,86,87 MJD/SCA388 and in a doxycycline-regulated mouse model of SCA1.89 Upon
shutting down mutant polyQ protein expression in these models, a reduction in the amount of
NIIs as well as behavioral phenotype improvement was consistently observed. Another example
was shown in a pan-neuronal conditionalDrosophilamodel of SCA7 in which the expression of
truncated protein was abolished leading to an increase in lifespan.90 Once this proof of concept
was obtained, several techniques targeting polyQ expression started being explored, including
the use of small interference RNA (siRNA) and short-hairpin RNA (shRNA) molecules. The
first description of interference RNA (RNAi) approaches for polyQ diseases was made in a
cell-based model, in which the inhibition of expression of a truncated version of the human
androgen receptor (AR) through double-stranded RNA strikingly reduced polyQ-mediated
cell death, caspase-3 activity, and protein aggregation.91 The applicability of RNAi in vitro
was further described in an SCA1 mouse model using shRNA for human ataxin-1 (ATXN1),
in which it was possible to observe an improvement in motor coordination, reduction in
NIIs, and restored cerebellar morphology.92 Later, microRNAs (miRNAs) suppressing the
expression of ATXN1-encoding mRNA, and subsequently reducing the protein levels, were
identified and shown to be efficacious in human cells.93 Recently, the miRNA miR-25 was
shown to be able to reduce both wild-type (wt) and polyQ-expanded mutant ataxin-3 (ATXN3)
protein levels, therefore increasing cell viability, decreasing early apoptosis, and diminishing
the accumulation of mutant ATXN3 protein aggregates in MJD/SCA3 cells.94 In another
miR-based approach, artificial miRNAs (non-allele-specific) targeting ataxin-7 (ATXN7) were
injected into the retina eye or into the brain at the deep cerebellar nuclei (DCN) of a transgenic
model of SCA7. The delivery of the miRNAs to the brain was shown to improve the motor
phenotype and neuropathology, namely of cerebellar Purkinje cell dendrites. Furthermore,
the artificial miRNAs injected into the retina of these mice were able to suppress 50% of
ATXN7 levels, with no adverse effects in retinal functioning.95 Extensive evidence supporting
the utility of RNAi therapy was also provided in models of HD using different viral vector
Medicinal Research Reviews DOI 10.1002/med
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to deliver shRNA silencing the mutant huntingtin (HTT). These treatments showed positive
effects, improving the motor behavior performance and limb clasping, as well as reducing the
NIIs in transgenic HD mice.96–98 In the case of MJD/SCA3, using lentivirus-mediated allele-
specific silencing of the mutant ATXN3 No´brega et al. were able to prevent the development
of the motor and neuropathological phenotypic characteristics of a model of the disease.99
However, the acute model system used did not mirror many aspects of the human disease, such
as ubiquitous expression of themutant protein, that in this case was restricted to the cerebellum,
and the hyperactivity phenotype that is not seen in humans. Furthermore, the efficacy of the
treatment was only assessed in a short period. To overcome some limitations of the model used,
the same authors have used RNAi approaches in a transgenic mouse model of MJD/SCA3.
In this study, the allele-specific silencing of mutant ATXN3 improved motor symptoms and
ameliorated the neuropathological features related withMJD/SCA3.100 In another study, using
miRNAs and a different MJD/SCA3 mouse model,101 with expression of the mutant ATXN3
under regulation of the endogenous promotor, a reduction of mutant ATXN3 was observed
in the cerebellum of the animals injected with miRATXN3 as compared to controls, and no
toxicity was found in the brain,102 which led the authors to pursue with a chronic preclinical
trial. In this preclinical trial, despite safety and lifelong suppression of ATXN3 expression in
the cerebellum, the motor impairment was not ameliorated in treatedMJD/SCA3 mice during
the study (11 months of assessment) and the lifespan was not prolonged by treatment.103
In summary, therapeutic application of RNAi to polyQ diseases has progressed remarkably
and reveals to be very promising due to the efficient and specific gene silencing. However, in
order for this technology to be used to full advantage in the human patients, several key
challenges still need to be overcome, namely regarding safety and delivery to the whole nervous
system. For instance, oral administration is not possible with current technologies and RNAi
formulations are limited to a few cell types and tissues. Also, tissue penetration, cellular uptake,
and entrance into the cytoplasm, as well as off-target and long-term secondary effects, still need
to be elucidated.104
2. Antisense oligonucleotide (ASO) Based Strategies
Another promising therapeutic approach to polyQ diseases, which are monogenic disorders, is
targeting the causative gene directly, ideally without affecting the normal allele (allele-selective
targeting) using oligonucleotides-based tools—ASOs-mediated strategy. Recently, Evers et al.
proposed an innovative strategy for MJD/SCA3 treatment, which consists of mutant ATXN3
protein modification without affecting its normal function. This approach includes the removal
of the toxic polyQ tract of ATXN3 using ASOs-mediated exon skipping, while keeping global
levels of ATXN3 unchanged. In this study, the authors used an ASO that effectively removed
simultaneously exons 9 and 10 of the ATXN3 mRNA(s) (the CAG repeat expansion is located
at exon 10) in human fibroblasts. The removal of these exons did not have a negative impact
in the ubiquitin binding capacity of ATXN3. To test the efficacy and safety of these ASOs
in vivo, the authors proceeded to a single intraventricular injection of the ASOs in the brain
of wt mice. After 7 days, the skipping efficacy was measured in the cerebellum of the mice,
which demonstrated a reduction in the levels of exons 9 and 10 and not of the adjacent exons,
suggesting the specificity of the ASOs used.105 No data are available yet concerning the long-
term safety or the efficacy of this approach in vivo regarding rescue of motor impairments and
other neurologic symptoms.
In HD extensive research has also been performed using ASO approaches. In R6/2 mice,
ASOs prevented the progressive brain atrophy.106 Furthermore, ASO-mediated suppression of
mutant HTT in the YAC128 mouse model was shown to improve the behavior phenotype and
improve some changes in gene expression observed in the striatum.107
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Interestingly, in the BACHD mouse model of HD, mutant HTT was suppressed for a
long time, even after the termination of the treatment.106 This study is in agreement with
clinical data in ALS patients, where an ASO (known to reduce the mRNA and protein levels of
mutant SOD1) was detectable in the spinal cord and in the brain of patients 3 months after an
intrathecal injection of ASO.108 The long half-lives of ASOs are particularly important in the
case of polyQ diseases, given their slow progression, which require chronic treatment. Recently,
a phase I clinical trial (NCT02519036) for HD, using huntingtin-targeting ASOs, has been
initiated in early-stage HD patients, to assess safety and tolerability.
3. Preventing Mutant Protein Aggregation
Although the question of relevant aggregation species (discussed below) is continuously de-
bated, it is more widely acknowledged that the polyQ proteins are toxic due to their aggregation
propensity when compared to their wt counterparts,36,109 leading to aberrant protein–protein
interactions. Supporting the toxic gain of function hypothesis are the findings that HTT aggre-
gates are toxic and are detected in the brain prior to neuropathological changes. Furthermore,
the generation of a HD model expressing mutant HTT and lacking endogenous HTT showed
that these animals presented the same HD-like characteristics when compared to animals ex-
pressing mutant HTT with a background of normal levels of endogenous HTT.110 On the other
hand, the loss of the protein normal function (through recruitment to inclusions or by ab-
normal conformation/interactions) might also contribute to the disease progression. Indeed,
animal models carrying mutant HTT and those lacking HTT normal function show some
similarities at pathological and behavioral levels, suggesting a contribution of a reduction in
the normal function of HTT to the HD phenotype.111 In accordance, a study in MJD/SCA3
showed that the lack of ATXN3 produced molecular alterations in a neuronal cell model that
overlapped those seen in cells overexpressing expanded ATXN3, and also in neurons from a
mouse model of MJD/SCA3, suggesting a contribution of an impaired function of ATXN3 to
MJD/SCA3 pathogenesis.112 In SCA1, in which the toxic gain of function hypothesis is well
accepted, additional data suggest that perturbation of a normal ATXN1 function contributes
to pathogenesis, namely through changes in specific interactions.113 In this line, it was shown
that lack of wt/endogenous copy of ATXN1, in a knock-in mouse model of SCA1 worsened
the mouse phenotype and led to gene expression alterations.113,114 Considering the arguments
favoring the toxic gain of function and the loss of normal function of polyQ proteins, it seems
reasonable to postulate that both may contribute to the disease progression, loss of function
likely resulting from aggregation and impaired protein–protein interactions.
In normal conditions, cells possess a robust multilevel protein quality control machinery,
to regulate homeostasis and guarantee that misfolded proteins do not accumulate and form
insoluble aggregates.115,116 This being a pathological hallmark of polyQ diseases, aggregation
reduction was one of the first therapeutic approaches used in the polyQ field. Chaperones or
heat-shock proteins (Hsp’s) are crucial proteins that maintain the normal folding and/or the
assembly of other macromolecular structures, and a defect in their normal function may per
se have pathogenic implications.117–119 A growing number of studies along the years reinforced
the idea that overexpression of molecular chaperones in cellular and animal models of polyQ
diseases has a protective effect, decreasing polyQ aggregation and/or neurodegeneration. In
1999,Warrick et al. showed that overexpression of Hsp70 was able to suppress polyQ toxicity in
a Drosophila model even with no detectable effect on aggregation.120 In cell models of SBMA,
the overexpression of Hsp70 and Hsp40 suppressed aggregate formation and apoptosis121 and
enhanced the degradation of expanded AR.122 The protective role of Hsp70 overexpression
was also observed in SCA1 cell, fly, and mouse models.123,124 In the case of MJD/SCA3, the
overexpression of two Hsp40s, DNAJ-1 and DNAJ-2, was able to suppress the aggregation
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of mutant ATXN3.125 Another molecule with the ability to increase Hsp70, the co-chaperone
Hip, was recently described to increase degradation of the mutant AR in cell culture and to
rescue toxicity in an SBMA Drosophila model.126 The heat-shock response (HSR; including
the production of chaperones) can be induced through activation of heat-shock transcription
factors (HSF), such as the heat-shock factor 1 (HSF-1), which has also been described to reduce
aggregation and cell death in polyQ disease cell models.127–129
Beyond overexpression or constitutive activation of HSFs using genetic tools, increased
HSR and HSP expression and protein folding can also be induced by a number of promis-
ing small chemical compounds. Trehalose, thought to act as a chemical chaperone, is able
to stabilize polyQ proteins in their native conformation130,131; however, it is also known to
be an autophagy inducer (discussed below).132 This compound was shown to be efficient in
HD cellular and animal models133 and recently in SCA17 mice.134 Geranylgeranylacetone, a
molecule capable of enhancing the expression of Hsp70, Hsp90, and Hsp105 through induc-
tion of HSF-1 activity, proved to inhibit nuclear accumulation of mutant AR, to ameliorate
motor behavior and increase survival in a SBMA mouse model.135 Extensive evidence sup-
ports the use of two analog compounds, 17-AAG and 17-DMAG, also capable of upregulating
Hsp40, Hsp70, and Hsp90, dependently on HSF-1 induction. They have been described to
have promising effects on aggregation load, toxicity, and motor behavior in several cell, D.
melanogaster, Caenorhabditis elegans, and mouse models of polyQ diseases.129,135–143 Recently,
the compound arimoclomol has been shown to ameliorate the symptoms in SBMA and ALS
mouse models, by boosting expression of chaperones Hsp70 and Hsp90, helping newly synthe-
sized proteins properly fold.144,145 Congo red, minocycline, and chlorpromazine are valuable
aggregation inhibitors in vitro and were tested in mouse models of HD; however, mild or no
improvement in phenotype was observed.146–148 Cystamine may also reduce polyQ aggregation
and increase survival by transglutaminase (TG) inhibition; TG has been proposed to crosslink
expanded polyQ proteins and facilitate their aggregation149 and was recently also linked to
autophagy induction150,151 (see below). This compound was beneficial for survival in HD mice
by decreasing HTT aggregation,152 but has not been tested in other polyQ diseases to date.
Another strategy in polyQ aggregation inhibition is centered on the use of small antibody
fragments called intrabodies, which are a biotechnological tool that can be used to disturb,
modulate, or define the functions, but also protein–protein interactions (and hence aggrega-
tion) of a wide range of target antigens at the posttranslational level.153 In the case of HTT,
intrabodies were described to reduce HTT aggregation and ameliorate neurological phenotypes
in HDmousemodels.154,155 InMJD/SCA3, only one aggregate-exacerbating intrabody against
fibrilar polyQ proteins was tested, causing an increased cytotoxicity and cell death in cells ex-
pressing mutant ATXN3.156 Targeting the intermediate species in the process of aggregation
and prevention of β-sheet dominant toxic conformation are also possible strategies that are
discussed in the Section 2.B.1.
4. Inhibiting the Cleavage of PolyQ Proteins
Expanded polyQ proteins are known to undergo proteolytic cleavage, generating smaller frag-
ments that can have a higher toxicity157,158 and/or more quickly aggregate.159 The “toxic
fragment hypothesis” suggests that proteolytic formation of polyQ fragments is a prerequi-
site of polyQ disease development. Therefore, modulation of the cleavage proteases’ activity
or decreasing the levels of toxic fragments seems to be a reasonable therapy approach for
polyQ diseases. Several proteolytic enzymes have been associated with the cleavage of polyQ
proteins. The first describedwere the caspases inHD,160 followed by calpains (a class of calcium-
dependent cysteine proteases); however, even if these proteases contribute to the majority of
cleavage effects, several other fragmentation events are observed which cannot be explained
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by their proteolytic activity. Interestingly, a number of studies in different cell and mouse
models demonstrated promising effects of caspase-1, caspase-3, and caspase-6 and calpain in-
hibition, as well as inhibition of matrix metalloproteinase (MMP) activity, in HD-associated
toxicity.161–166 The cleavage of mutant HTT by caspase-6 has been suggested to be required
for the HD-related behavioral phenotype and selective neuropathology in the YAC128 mouse
model of HD. Supporting this idea, caspase-6-resistant mutant HTT mice presented a delay in
nuclear translocation of expanded HTT.167 More recently, a transgenic mouse expressing the
N-terminal 586 aminoacids ofHTT, a putative cleavage fragment resulting of caspase-6 activity,
showed behavioral deficits as well as nuclear accumulation of HTT aggregates. Although their
phenotype was less severe than that of HD mouse models expressing shorter fragments, these
studies suggest that the caspase-6 fragment may be an intermediate of the cascade leading to
disease progression.168 In DRPLA, atrophin 1 is also cleaved by caspases at aspartate 109, and
cleavage site mutations reduce nuclear localization, aggregate formation, and cytotoxicity.158
This was also shown in the context of MJD/SCA3, in which general caspase inhibition in a
Drosophilamodel delayed the neurodegeneration progression caused by the expanded ATXN3
expression.169 Targeting the expression of calpains was also proposed as a therapeutic approach
inMJD/SCA3,170–172 this inhibition being able to prevent the nuclear localization, aggregation,
and toxicity ofATXN3.Recently, itwas also described that knockdownof calpain (formCalpA)
in aDrosophilamodel ofHD leads to autophagy-dependent protection against polyQ toxicity.173
Caspase or calpain by small molecules inhibition could therefore have beneficial effects,
through a decrease in generation of mutant proteins fragments. In fact, a general caspase in-
hibitor, z-Val-Ala-Asp-fluoromethylketone, extended lifespan and ameliorated the rotarod per-
formance in R6/2 mice.166 The combined administration of caspase-1 and caspase-3 inhibitors,
Tyr-Val-Ala-Asp-chloromethylketone and Asp-Glu-Val-Aspaldehyde-fluoromethylketone, re-
spectively, also increased the lifespan in HD mice.174 z-DEVD-fmk, another caspase inhibitor,
was found to inhibit HTT cleavage and toxicity in a cell model of HD.162 When administered to
a lentiviral mousemodel ofMJD/SCA3, BDA-410, a calpain inhibitor, was able to decrease the
formation of both cleaved and full-length ATXN3 forms, as well as to reduce ATXN3 aggre-
gation. Moreover, BDA-410 prevented motor deficits and preserved cerebellar morphology.175
Finally, cystamine, a transglutaminase inhibitor (see above) able to increase lifespan of a HD
mouse model, was also shown to reduce caspase activity.176
Another strategy is to modulate protease activity through alternative pathways. For ex-
ample, the levels of caspase-1 and caspase-3 were decreased by treating R6/2 mice with the
tetracycline derivative minocycline, retarding the disease progression and death.177 Curiously,
minocycline is a multifunctional compound, and was also described as an aggregation (see
Section 2.A.2) and apoptosis inhibitor (see Section below 2.A.7). Recently a gene therapy ap-
proach to cleavage reduction was also proposed, using ASO-mediated mRNA (an approach
discussed previously) and protein modification. The authors showed that modulating cleavage
by inducing the skipping of exon 12 inHTT pre-mRNA inhibits the formation of anN-terminal
fragment involved in HD toxicity.178
The generation and development of protease inhibitors able to prevent the conversion of
polyQproteins intomore toxic fragments seems to be a promising therapeutic strategy.However,
caution is warranted with these inhibitors concerning specificity, since there are several other
essential signaling pathways in which proteases are involved179,180 could also be affected. Ulti-
mately, in vivo validation of the efficacy, safety, and tolerability of these approaches is required.
5. Inducing Mutant Protein Degradation: UPS and Autophagy
Increasing the clearance of the mutant polyQ proteins to avoid their toxic downstream effects
has been a focus of therapeutic strategies for several years. Cellular mechanisms for degrading
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unwanted proteins include the UPS and autophagy. In several cellular and animal models of
polyQ diseases, as well as in the patients’ postmortem brains, polyQ inclusions co-localize with
Ub and proteasome subunits, raising the possibility of UPS involvement in these diseases.123,181
Some studies show that stimulating ubiquitylation and degradation of polyQ proteins through
the UPS can rescue pathology in cell and animal models. By increasing UPS activity, Y-27632
(already known to be a rho-associated kinase inhibitor but also used in clinical trials as an
anti-ischemic, anti-vasospastic, and anti-hypertensive agent) decreased polyQ toxicity in an
HD Drosophila model182 (an effect first identified in an unbiased drug screening, see Section
2.B.1), and reduced aggregation levels of mutant HTT and ATXN3 cell models, through its
capability ofmodulating bothUPS and autophagy.183,184 Another compound shown to increase
the enzymatic activity of the UPS was amilorid and its derivative, benzamil, also widely used
in clinics as diuretics to treat or prevent hypokalemia in people with high blood pressure185;
treatment with these compounds led to a reduction of mutant protein aggregation and toxicity
in HD models.186
An additional strategy is the direct modulation of proteasome function. USP14 is a deu-
biquitylating enzyme (DUB) connected with the proteasome, which blocks the degradation of
ubiquitylated substrates. IU1, a selective small-molecule inhibitor of USP14, was described to
accelerate proteasomal degradation of polyQ proteins, such as ATXN3, but also of other pro-
teins associated with neurodegenerative diseases such as tau, TDP43, and oxidized proteins.187
However, since loss of function of Usp14 in the mouse gives rise to cerebellar ataxia, some
caution must be taken with this approach.188
E3Ub ligases are enzymes that determine the substrate UPS specificity within the UPS and
in ubiquitin signaling in general. The overexpression of Ub ligase CHIP (C terminus of Hsc-
70-interacting protein) confers neuroprotection by enhancing ubiquitylation and consequent
clearance of polyQ-expanded proteins, delaying the disease phenotype in SCA1, MJD/SCA3,
and SBMA animal models.189–191 Parkin, another E3, was also shown to ubiquitylate ATXN3
reducing polyQ toxicity in cells.192,193 More recently, it was shown that the Nrf1 and Nrf2
transcription factors (known to regulate the oxidative stress response)194 can also regulate the
UPS.
Sulforaphane is a small molecule capable to induce Nrf2 activation, and therefore increase
proteasome levels and activity195,196 as well as enhance UPS function in vivo.197 Through this
action, this molecule was able to decrease the mutant HTT and alleviate polyQ toxicity in
neuronal mouse cells.197 These studies suggest that the UPS is a versatile system that can
be targeted to increase the clearance of polyQ-expanded proteins, the main challenge being
modulating this system in an effective and specific manner.
Autophagy is another prominent therapeutic target for the degradation of aggregated
proteins, and it is negatively regulated by the mammalian target of rapamycin (mTOR).198
Upregulation of autophagy by inhibiting mTOR with rapamycin showed beneficial effects in
different animal models of neurodegenerative diseases by enhancing autophagy function.199–203
For example, a rescue of polyQ toxicity in cell, fly, and mouse models was observed upon
rapamycin treatment, in parallel with an increase in the clearance of both soluble and insoluble
species of the expanded polyQ proteins.204,205 Curiously, a selective ATP-competitive small
molecule known as torin1 has been described to inhibit mTORC1 activity and consequently
increase autophagy to a higher extent than rapamycin206; however, it still needs to be tested
in polyQ disease models. Also tackling mTOR inhibition, Ravikumar et al. showed that by
increasing intracellular glucose levels, mutant HTT clearance was enhanced and mutant HTT
aggregates decreased.205
Autophagy can also be modulated independently of mTOR by the use of several com-
pounds, such as lithium chloride (LiCl), sodium valproate, carbamazepine, rilmenidine, and
other molecules that inhibit inositol monophosphatase.207,208 Since some of these compounds
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have been used for several years to treat human CNS and heart diseases, they may be easily
translated to the clinics if they have promising effects in polyQ diseases. LiCl treatment ame-
liorated motor performance and depression in an HD mouse model upon postsymptomatic
treatment, with no effect in survival.209 In SCA1, treatment of the knock-in mouse model
with LiCl also improved the neurological and pathological phenotypes.210 In contrast, in the
case of MJD/SCA3, LiCl therapy led to no overall improvement in motor function in the
CMVMJD135 mouse model211 nor in patients (see Section 3). Rilmenidine is an antihyper-
tensive agent that was also tested in an HD mouse model, leading to amelioration of the
disease symptoms and also to a reduction in the mutant HTT levels.212 Other approaches may
consist of modulating the expression of specific proteins or molecules known to induce au-
tophagic degradation.213,214 For instance, upon C.elegans bec-1, Ce-atg7, and Ce-atg18 gene
knockdown or knockout, the polyQ aggregate formation and polyQ-expanded protein toxicity
increased.215 Therefore, modulating these autophagic genes in the opposite direction could
enhance the autophagic polyQ degradation. Overexpression of histone deacetylase 6 (HDAC6)
lea to an induction of the autophagy process compensating for UPS impairment in an SBMA
Drosophila model.216 More recently, the lentiviral vector-mediated overexpression of beclin-1
was described to enhance autophagy and to be protective in neuronal and in lentiviral-based
rat model of MJD/SCA3.217 Interestingly, 17-DMAG, an HSP90 inhibitor predicted to induce
chaperone expression and thus promotemutant protein refolding and/orUPSdegradation, was
shown to function as an autophagy inducer in the CMVMJD135mouse model ofMJD/SCA3,
improving motor uncoordination, and reducing NIIs.142
Trehalose, a compound already described in the above section as a chemical chaperone
able to influence protein folding, is also an mTOR-independent autophagy inducer that can
enhance clearance of aggregation-prone mutant HTT132 and ATXN3218 and protect against
apoptotic insults in cells via its autophagy-inducing properties.132 The combinatory effects of
its autophagy-inducing and chemical chaperone activities, together with its lack of toxicity,
places trehalose as a potentially interesting compound for polyQ disease therapy.
A combination treatment strategy for inducing autophagy to a higher level may also be
considered. The combination of lithium or L-690,330 with rapamycin was shown to lead to
enhanced clearance of mutant HTT and higher protective effects in HD cell and fly models,
compared to treatment with either drug alone.207,219 The lithium and rapamycin combination
treatment was also a proposed approach (considering the extra protective effects of GSK-3β
inhibition by lithium) that appeared to be cytoprotective in cell models of HD.219–221 Studies
in an MJD/SCA3 mouse model, however, did not confirm the efficacy or safety of a similar
combination of lithium with CCI-79, a rapamycin analog, which led to neurotoxicity.222
Additional relevant studies on autophagy were also reported using unbiased drug screen-
ings as discussed below. Overall, the UPS and autophagy induction strategies seem to be
attractive; however, it is important to identify new safer and more tolerable small-molecule
autophagy modulators to be used in the chronic treatment of poly Q diseases.223
6. Mitochondria Stabilization and Reduction of Oxidative Stress
Mitochondrial dysfunction and oxidative stress play an important role in polyQ pathogenesis.
Several compounds improving energymetabolism defects or reducing oxidative stress have been
successfully tested in cellular and mouse models of polyQ diseases (discussed below). Although
the degree of oxidative stress involvement is not completely known, and while this can be seen
as a very “downstream” event in the pathogenesis of polyQ diseases, antioxidant treatment may
be able to exert important neuroprotective effects. Coenzime Q10 (CoQ10) is a cofactor of the
electron transport chain that supports mitochondrial energy generation, preserves cell viability,
acts directly as a potent antioxidant in vivo, and induces increase of mitochondrial vitamin E
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concentrations.224 Cotreatment with CoQ10 and remacemide, an NMDA receptor antagonist,
improved neurological symptoms and extended survival in different models of HD.244 In con-
trast, this combinatory approach showed no overall effect in HD patients225 (see Table III).
CoQ10 alone was also able to reduce weight loss and NIIs as well as greatly improve the motor
performance in the R6/2 mouse model of HD.226,227 Supplementation with CoQ10 together
with creatine, which provides a source of energy to compensate for reduced efficacy ofmitochon-
dria, also revealed additive neuroprotective effects in HDmodels.228 Creatine supplementation
per se was also able to improve brain pathology, phenotype as well as increase survival in
the R6/2 mouse.229 Also in the N171-82Q model of HD, survival was extended with creatine
treatment.230 Despite the disappointing results in one human study that showed no effect of
creatine in HD patients,231 a more recent study showed positive results in HD presymptomatic
carriers. In this study, 60 patients (including diagnosed premanifest and nontested at-risk) were
given a high dose of creatine for 18 months that showed to be safe and well-tolerated by the
patients. Interestingly, neuroimaging in these patients demonstrated treatment-related slowing
of cortical and striatal atrophy at 6 and 18 months, suggesting creatine as a promising therapy
for HD if initiated early on232 (see also Table III).
Resveratrol, a natural phenol with antioxidant and sirtuin modulation activities, reduced
mutant polyQ toxicity in neuronal cells and C. elegans model of HD.233,234 Recently, Cunha-
Santos et al. demonstrated that this antioxidant, also known as sirtuin 1 (SIRT1) activator,
improved balance and motor deficits in a MJD/SCA3 mouse model, when administered after
disease onset. This study pointed SIRT1 modulation by resveratrol as a potential therapeutic
target for MJD/SCA3.235
Tauroursodeoxycholic acid (TUDCA) is a hydrophilic endogenous bile acid with multi-
ple neuroprotective properties, including antioxidant and anti-apoptosis activities. This com-
pound was shown to decrease the apoptosis of striatal neurons and to improve motor and
cognitive deficits in HD mouse models.236 Several other molecules with known antioxidant
activity, such as melatonin, selenium, quinolinic acid, idebenone, lycopene, lipoic acid, pyru-
vate, and L-carnitine, also proved to exert neuroprotective effects in HD models (reviewed
in 237).
Also related with this group of targets is the Nrf2/antioxidant response element (ARE)
signaling pathway, which is involved in antioxidant and anti-inflammatory responses.194 For
example, the triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide were described
to upregulate Nrf2/ARE genes, thereby reducing the oxidative stress and striatal atrophy,
improving the motor deficits, and increasing lifespan in the N171-82Q mouse model of HD.238
Together, these results indicate that a therapy based on antioxidants and other promising
molecules capable of improving mitochondrial function and reducing oxidative stress could be
effective for polyQ diseases, particularly for HD.
7. Transcription Modulation
The current conceptual model is that mutant polyQ proteins frequently interact abnormally
with histone acetyltransferases (HATs) and/or histone deacetylases (HDACs), changing physi-
ological histone modification patterns and thus altering gene expression.239 The normalization
of the dysregulated gene transcription, usually by targeting histone acetylation andmethylation,
has been a growing field of research. The inhibition of HDAC activity, as a repressor of tran-
scription, has been proposed as a transcription normalization method, and is the most widely
tested in mouse models of polyQ diseases. Although HDAC inhibitor (HDACi) molecules fre-
quently lack specificity, because they may also perturb the expression of other unrelated genes,
some of them do exhibit promising therapeutic properties.
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Molecules with HDACi activity such as sodium butyrate (SB), phenylbutyrate, suberoy-
lanilide hydroxamic acid (SAHA or vorinostat), and valproic acid (VPA) or its salt derivative—
sodium valproate, which are proposed to increase gene expression (albeit in a very nonspecific
manner), have shown efficacy in a variety of polyQ disease models. Pharmacological treatment
of the R6/2 transgenic mouse model of HD with SB improved body weight loss and motor
phenotype, significantly extended the lifespan by more than 20%, and delayed the neuropatho-
logical damage; this was proposed to happen through the increase in acetylation of H3 and H4
and also of the transcription factor SP1.240 An improvement in neurological phenotypes to-
gether with an increased acetylation of histones was also observed in transgenic mouse models
of SBMA,241 DRPLA,242 MJD/SCA3,243 and in a conditional pan-neuronalDrosophilamodel
of SCA790 treated with SB. In spite of significant improvements in many neuropathological
phenotypes, SB was not able to reduce the mutant polyQ protein aggregation in some of the
models,240,241 apparently acting downstream or independently of the aggregation component
of the disease. Another HDACi, phenylbutyrate, reduced brain atrophy and ventricular en-
largement, and improved lifespan in the N171-82Q transgenic model of HD.244 SAHA has
been tested in the R6/2 model of HD showing beneficial effects in the motor phenotypes and
neuronal atrophy, however with no improvement in body weight. Like SB, SAHA rescued
the hypoacetylation of histones in these animals, but had no effect on polyQ aggregates.245
More recently, the same authors demonstrated that SAHA decreased HDAC2 and HDAC4
at the protein level in the cortex and brainstem, but not at the mRNA level.246 SAHA was
also described to induce autophagy,247,248 which could contribute to its beneficial effects in
polyQ disease models; however, the lack of effect on aggregation suggests the opposite in this
case. VPA (or its salt—sodium valproate with pharmacokinetic similarity) is a well-tolerated
antiepileptic drug, also with HDACi properties. This compound (or its salt) has been proven to
delay the disease onset, reduce neurological deficits, and/or prolong survival in several models
of neurodegenerative diseases, including HD, SBMA, and ALS.249–251 In MJD/SCA3, VPA
(a multitarget compound) was reported to alleviate neurodegeneration in a Drosophila model
of the disease252 and attenuate mutant ATXN3-induced cell toxicity in a human neuronal cell
model,253 while only mild effects in the CMVMJD135 mouse model.254 In contrast, safety and
efficacy of VPA was suggested in a clinical trial with MJD/SCA3 patients (see Section 3).255
Thomas et al. successfully treated the R6/2 model of HD with a benzamide-type HDACi,
HDACi 4b. This compound showed a lower toxicity in vitro when compared with previously
tested HDACis, together with prevention of motor deficits and neurodegenerative processes in
a postsymptomatic treatment approach.256
Other chromatin remodeling approaches, though not so well studied as the previous ones,
comprise for instance the repurposing of chromomycin and mithramycin antibiotics, which
were able to rescue the downregulation of a subset of affected genes, improve motor and neu-
ropathological phenotypes, and increase the lifespan of transgenic mouse models of HD.257,258
Another compound shown to alleviate the transcriptional dysfunction of HD models was the
phosphodiesterase type IV inhibitor rolipram, which increases the phosphorylation and activity
of CREB. Rolipram ameliorated neuropathology, slowed progression of neurological pheno-
type, and extended lifespan in R6/2 mice. Additionally, BDNF levels, which are decreased
in this HD mouse,259,260 were increased in treated mice through restored CREB function.261
A subsequent study showed that rolipram also prevented the sequestration of CREB-binding
protein (CBP) into NIIs.262 Dimethylcurcumin (ASC-J9), a drug that specifically disrupts the
interaction of the mutant AR with CBP, was shown to be symptomatically beneficial in the
AR-97Q SBMA mouse model.263
In spite of the promising results obtained with HDCAi’s in the polyQ disease field, a
major drawback of this strategy is that it still lacks specificity. In addition to their modulation
of the transcriptional defects, HDACi’s can also increase the acetylation of other nonhistone
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proteins, such as tubulin264 and Hsp90,265 and modify levels of HSPs266,267 via transcription-
independent mechanisms. While some of the effects can add to their beneficial action, other
issues stickle the translation of the promising results to the clinical context, contributing to
some associated toxicity. Further studies of their actual molecular mechanism of action, and
development of more selective HDACi’s with less toxicity, might offer better opportunities.268
Also, and assuming the increasing knowledge on HATs and their function in neuronal survival,
the stimulation of HAT function appears to be another new therapeutic possibility in this
field.269 Lastly, more detailed studies on the epigenetic mechanisms underlying polyQ diseases
may be relevant for the development of future therapeutic approaches.
8. Other Therapeutic Targets
The overactivation of NMDA glutamate receptors and consequent excitotoxicity leading to
neuronal death has been proposed to play a role in the pathogenesis of HD.270 Supporting this
concept, the use of compounds that block the excessive glutamate release, as riluzole, has shown
efficacy in HD mouse models concerning survival, motor performance, and aggregation.271 A
small study in human HD patients (see Table III and Section 3) showed some benefic effects
in chorea intensity.272 Yet, a larger and longer study demonstrated no effect of riluzole in HD
patients,273 suggesting that riluzole treatmentmay not useful in these patients. Postsymptomatic
treatment of a conditional mouse model ofMJD/SCA3 with riluzole led to no improvement of
themotor uncoordination; intriguingly, riluzole chronic administration decreased theCalbindin
expression in Purkinje cells of the cerebellum, suggesting possible toxicity.274 In contrast, a
randomized clinical trial in SCA patients of different etiologies showed the short-term efficacy
(4 and 8 weeks) of riluzole in reducing disease symptoms. This was confirmed in a 12-month,
multicenter, double-blind randomized trial including 55 patients, also with different types of
hereditary ataxia, including some with polyQ-related ataxias.223–225 Since MJD/SCA3 patients
were not included in the abovementioned SCA clinical trials, the results of preclinical and
clinical trials are not really conflicting; however, they suggest that further studies may be
required with genetically homogeneous patient populations, in which attention should also be
paid to the interpretation of the SARA score outcomes, trial design, sample sizes, and patient
followup, as was discussed by several authors223–225 (see Section 3).
Furthermore, two other compounds affecting the glutamate levels in the synaptic cleft,
LY379268 and 2-methyl-6-(phenylethynyl)-pyridine, significantly increased the lifespan ofR6/2
mice.275 Administration of remacemide (NMDA antagonist) and/or of CoQ10 also prolonged
the lifespan of HD mice.226
Recently, administration of the β-lactam antibiotic ceftriaxone, known to promote synaptic
glutamate clearance by astrocytes, thereby reducingCa2+ influx,was shown to improve behavior
deficits in SCA28 mice when administered either prior to or after symptom onset, showing an
additional potential strategy for treatment.276
Another option is apoptosis inhibition; anti-apoptotic drugs, such as minocycline and
caspase inhibitors have shown promise in polyQ animal models. Administration of minocycline
to R6/2 mice extended their survival,174 and when combined with CoQ10 further improved
survival, neuropathology, and motor phenotype when compared with any of the treatments
alone.277 However, long-term studies will be required to find out possible side-effects associated
with suppression of these key cellular pathways at the organism level.
Other still emergent strategies for polyQ diseases may comprise neural cell replacement
therapy and neuroprotection strategies. The replacement of dead and/or damaged neurons by
new neural cells with the proper ability to integrate, function,278 and also contributing to neu-
rogenesis and the production of trophic factors279,280 may provide additional neuroprotection
and promote the reestablishment of neuronal homeostasis. The attractiveness of these strategies
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lies partially in the fact that they might be effective even after disease manifestation, but many
technical hurdles are still in the way of their translation to the clinic.281–283
B. Unbiased Drug Screenings (Hypothesis-Free Approaches)
Candidate-based drug design and testing, although a theoretically rational approach, is only
one of the possible strategies for drug discovery, and although this approach can offer promising
results, it is limited to known targets and drugs and it cannot unravel novel targets and disease
pathways.
In the last years, unbiased drug screenings for polyQ therapy discovery are gaining rel-
evance due to their numerous advantages and the novel technical possibilities for screening.
High-throughput screening (HTS) allows the unbiased testing of the effects of thousands of
compounds in one ormore biological assays. The smallmolecules used inHTS’s are often readily
commercially available and are generally classified into three groups: (i) Food andDrugAdmin-
istration (FDA)/European Medicines Agency (EMA) approved compounds, which comprise
bioactive, natural products and synthetic small organic molecules already in use in humans,
being studied with the aim of repurposing or repositioning for different diseases than those
they have been used on; (ii) novel synthetic compounds, comprising a vast collection of novel
organicmolecules; and (iii) novel natural products. The FDA/EMA-approved compounds have
the potential to rapidly translate into the clinic and of a faster interpretation of pathophysio-
logical mechanism due to previous knowledge on their targets and mechanisms of action. The
synthetic compounds may comprise molecules for additional targets can be easily improved
and modified to increase potency and reduce side effects, being produced at significant lower
costs. The natural products may also contain novel structures and may be superior in terms of
biological activities and chemical complexity but are usually associated with higher production
costs and/or limited availability and extract reproducibility challenges. However, they are an
excellent starting point for novel compound discovery.
Besides the compound library selection, the most critical step is the choice of the biological
readout, whichmust be key to the disease process and be compatible with automation. In polyQ
diseases, drug discovery is hampered by the lack of robustly validated targets and the incomplete
knowledge of the molecular pathways. Nevertheless, the strategy consists of screening against a
specific disease hallmark in the available cellular or simple/invertebrate animal models, which
need to recapitulate at least some disease-associated characteristic. In these diseases, the most
common target has been polyQ protein aggregation, which is an important aspect of cellular
pathology, either as a primary event or as a robust indicator of abnormal protein conformation
and of cellular and proteostasis impairment. Other described targets for polyQ HTS have been
cell death, mutant protein clearance (degradation), transcriptional dysregulation, and other
events leading to toxicity. Any such model will have intrinsic advantages as well as limitations.
A summary of described HTS’s published to date in polyQ diseases is presented in Table
II. Although the majority of the HTS’s have been centered on HD, several concepts could
potentially be applied to the other polyQ diseases.
1. Aggregation Assays
The first drug screenings were planned to identify compounds that would avoid the formation
of HD aggregates or disrupt them in vitro. Examples of these assays include aggregate quan-
tification by filter retardation assay with fluorescent ELISA readouts.284,285,287,290 Although
optimization of this method required much more time than the current HTS’s, Heiser et al.
were able to screen 184,880 small molecules and identified 25 benzothiazoles able to inhibit
aggregation of the HTTQ51 protein, some of them being already described to be promising for
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ALS treatment.314 As a second assay, these compounds were tested in HEK293 cells expressing
HTTQ51, the majority of them being toxic to cells. This emphasizes the risks of translation
from in vitro to cell cultures and, ultimately, to the in vivo context. Another in vitro aggregation
assay with a longer HTT fragment was performed byWang et al., who identified 19 compounds
inhibiting aggregation by more than 50%.285 Curiously, one of the hits was celastrol, an anti-
inflammatory and antioxidant compound that has also been proposed for AD therapeutics.315
To incorporate cellular context, a pioneering screen to monitor polyQ aggregation in cells was
developed using a fluorescence resonance energy transfer (FRET) based assay that is based on
the transfer of energy between two fluorophores that are in close spatial proximity. With this
method, Pollit et al. screened a 2800 compound library and identified the Rho kinase (ROCK)
inhibitor Y-27632 as a hit compound182 decreasing mutant AR aggregation; they subsequently
validated its beneficial effects in a Drosophila model of HD. The discovery of the ROCK
inhibitors in the context of aggregation allowed the characterization of the ROCK-profilin
signaling pathway.316,317 The FDA-approved ROCK inhibitor HA-1077 was shown to rescue
retinal degeneration in the R6/2 mouse model of HD, showing that ROCK signaling inhibition
is an HD-relevant mechanistic pathway.318 With the same strategy, the group screened a set of
biologically active compounds and found hits capable of inhibiting the aggregation of a pure
polyQ stretch in HEK293 cells, suggesting these compounds as essential tools for understand-
ing and counteracting the aggregation mechanisms in polyQ diseases. Some of the compounds
were also able to alleviate the neurodegeneration in a Drosophila model of HD.291 Recently,
Fuentalba et al. developed a robust and quantitative method to assess protein aggregation
dynamics, using aggregation-sensitive luciferase-based reporter to quantify polyQ aggregation
in cellulo, based on an expanded HTT fragment.289 With this method the authors identified
leflunomide and its active metabolite teriflunomide, as preventing incorporation of expanded
polyQ proteins into aggregates. This compound could therefore hold promise for polyQ dis-
eases, with the additional benefit that it was already tested in multiple sclerosis patients in
a phase III clinical trial, resulting in the decrease of annualized relapse rate and the lesion
volume; however its long-term safety profile remains unknown.319 In addition, the efficacy of
teriflunomide was also confirmed in yeast systems. This biological system is less susceptible to
polyQ-mediated toxicity, and easily subject to genetic analysis, allowing the study of multiple
cellular factors in the aggregation process. In 2005, a primary aggregation-based screen was
performed with 16,000 compounds in a yeast strain, using a galactose-inducible HTT construct
with 103Qs tagged with EGFP.292 Nine hits were identified and microscopically validated. Four
of the compounds were found to inhibit the aggregation of this fusion protein also in PC12 cells.
However, the compounds’ activity was weak in a cell-filter retardation assay, demonstrating
that they did not interfere directly with polyQ aggregation. A recent study also used a yeast
model of polyQ proteotoxicty to screen a large amount of natural product extracts, identifying
actinomycin D as a strong inhibitor of polyQ aggregation, an effect that was accompanied by
its impact in increasing the levels of different chaperones.293 This compound also suppressed
aggregation in mammalian cells, suggestive of a conserved mechanism and therefore placing
this as an interesting compound for polyQ diseases. Efforts were also made to establish brain
slice assays that could closely mirror the aggregation events in mouse models of HD,320–323
and although the authors could confirm the anti-aggregation properties of Congo red in this
system, the predictive value of this assay for the compounds’ activity in animals and patients
still needs to be confirmed.
Targeting intermediate species in the process of aggregation could also be a strategy for
therapy. Taking this into consideration, the compounds able to decrease the oligomeric species
rather than insoluble inclusions may be considered as more interesting therapeutic candidates.
Indeed, a compound designated B2, was identified in a drug screening and shown to pro-
mote HTT aggregation and to decrease cytotoxicity in a cellular model of HD.324 Following
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studies also demonstrated the ability of B2 to increase aggregates in cellular models of SBMA,
and significantly decreased the extent of alteration of the eye phenotype in a fly model of
SBMA.325
Another example comes from the screening of a library of 5000 natural substances,
in which (–)-epigallocatechin-3-gallate (EGCG), a green tea polyphenol, was identified as an
inhibitor of HTT aggregation in vitro. This compound reduced toxicity and aggregate load in a
yeast model of HD and when administered in aDrosophilamodel of HD, it allowed a reduction
in photoreceptor degeneration andmotor impairment. EGCG seemed to exert its positive effect
on aggregation in vitro by suppressing the formation of small oligomers and stimulating the
formation of larger aggregation species.290
Additionally, some evidence supports the notion that the expanded polyQ segment confers
a new three-dimensional conformation to the proteins.326 The “Exposed β-sheet” theory is
based on the possibility that expanded units of polyQ proteins establish strong hydrogen
bonds with each other, leading to the formation of insoluble parallel β-sheet structures,327 and
ultimately to their accumulation as inclusion bodies in the neurons. Considering this hypothesis,
compounds targeting the abnormal protein conformation and the subsequentβ-sheet formation
process might constitute a useful therapeutic strategy. Considering the existence of an antibody
that recognizes the conformation of an expanded polyQ tract (1C2) in a specific manner,
peptides that can specifically bind to pathogenic polyQ domains could inhibit the interaction
of the monomers with each other and slow/prevent the aggregation and the neurodegenerative
process.286,328 Using a peptide library screening, Popiel et al. found the polyQ-binding protein
1 (QBP1) as an inhibitor of the toxic β-sheet conformational transition and aggregation of
the expanded polyQ in vitro. The treatment of a Drosophila model of HD with this compound
was shown to prevent conversion of the expanded polyQ into its aggregation-prone β-sheet
conformation, resulting in a neuroprotective effect.328,329 Nevertheless, this peptide was shown
to be too large to cross the cell membrane and to reach the intracellular polyQ protein efficiently.
The fusion of protein transduction domains (PTDs) enabled the intracellular delivery of QBP1,
inhibited polyQ aggregation and suppressed polyQ inclusion body formation and cytotoxicity
in vitro.330 Oral administration of PTD-QBP1 suppressed polyQ-induced premature death and
inclusion body formation in a Drosophila model of MJD/SCA3.330,331 However, in the R6/2
mousemodel ofHDweight loss phenotype only improvedwhen thismolecule was administered
via intraperitoneal injection, showing oral administration to be ineffective.332
Recently, another peptide tested as a candidate-based molecule, P42 (part of the endoge-
nousHTT protein and lies within a region rich in proteolytic sites), was found to exert beneficial
effects in a Drosophila HD model.333 To further test the beneficial effects of P42, Arribat et al.
tested it in the R6/2 mouse model of HD, using a systemic delivery route of administra-
tion. For that, they used a combinatory approach fusing P42 to the protein transduction
domain of the HIV TAT protein, allowing the delivery to living cells via endocytosis. Also,
they used a novel water-in-oil microemulsion drug delivery vector called Aonys, providing a
transmucosal route of administration. P42 daily administration showed to be safe and to im-
prove behavior deficits observed in the R6/2 mice as well as to reduce HTT aggregates and
astrogliosis.334
Chen et al. generated chemically a library of 60,000 of peptoids (oligomers ofN-substituted
glycines) that was screened formolecules that specifically bound to an amino-terminal fragment
of mutant HTT protein, in order to overcome delivery issues of the peptides. This screening
resulted in the identification of HQP09. This peptoid prevented the aggregation of mutant HTT
in vitro and in YAC128 medium spiny neuron (MSN) cultures MSNcultures, also stabilizing
glutamate-induced Ca2+ signals and protecting them from glutamate-induced apoptosis. In
vivo, intracerebroventricular delivery of HQP09 to the YAC128 HD model resulted in reduced
accumulation of mutant HTT aggregates and improved motor performance.332
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Diverse in vitro and cell-based assays have allowed the identification of small molecule
aggregation inhibitors, some of which were also found to be active in vivo (e.g., in theDrosophila
model). Despite the encouraging results with the aggregation assays, some limitations are still
present. Particularly, the evaluation of the toxic effects of the compounds at early stages should
be improved and the use of different model systems might contribute to variable outcomes of
the same compound, suggesting that the same library of compounds should be tested in several
model system of the disease in study.
2. Cell Death Assays
In addition to aggregation assays, more complex biological assays aiming at phenotypic end-
points associated with the disease process could be used. Although the exact role and timing of
cell death in polyQ pathogenesis is still discussed,335,336 this downstream consequence of toxic-
ity is being used as an assay readout for the identification of novel small molecules. Caspase-3
activation is a key event in apoptotic cell death and its genetic or small molecule inhibition
showed to be beneficial in cell culture and mouse models of HD.337,338 A cell-based assay was
used to identify inhibitors of caspase activation in a model of SBMA, in which expression of
mutant AR Q112 induces caspase-3 activation and cell death.294 A 1400-compound collection
was screened and the researchers identified 15 compounds inhibiting caspase-3 activity bymore
than 70%; however, only four cardiac glycosides were confirmed to enhance cell viability and
not cause cytotoxicity. Curiously, these compounds did not inhibit caspase-3 directly, suggest-
ing that they target upstream players in the cascade of death pathway. Thus, the study of the
mechanisms of action of these compounds could disclose new and unexpected biological targets
in HD.
Apart from this cell death related molecular endpoint, there are also HTS’s based on the
phenotypic endpoint, cell death itself. Aiken et al. used an inducible PC12 cell model, with a pre-
viously described construct containing 103Q’s,339 which underwent rapid cell death, and quan-
tified lactate dehydrogenase (LDH) release or measured mitochondrial activity with an MTS
assay. With this model, the group screened 1040 compounds and identified 12 that completely
rescued cell death. Among these compounds, cannabinoids (-8-THC,-9-THC, cannabinol,
and cannabidiol) were identified as efficient for protection against cell death,295 through a pos-
sible mechanism related with their described antioxidant effects.340 Another screen with the
same set of compounds, in an inducible PC12 cell model, but with a construct with 148Qs,
identified five compounds able to prevent cell death, three of them (acivicin, nipecotic acid, and
mycophenolic acid) also decreasing aggregation.296 It is important to note that, although these
two HTS’s were performed with the same inducible model and the same compound library, no
overlap was found in the hit compounds, with the exception of caspase inhibitors.
One cannot stress too much the importance of the cellular model and polyQ construct
when designing the assay. Thus, it is valuable to performHTS’s in cell lines that mirror as much
as possible the cell types known to be affected in the disease context. With that purpose, Varma
et al. used a stable striatal neuronal cell line expressingN-terminal 548-aa fragment ofHTTwith
120Qs, which undergoes cell death upon serum deprivation at 39ºC.297 In a collection of 43,685
compounds, they identified 29 hits rescuing cell death specifically in mutant but not in parental
striatal cells, suggesting that these compounds are specifically activated by mutant HTT and
consequently are possibly relevant therapeutic targets. As secondary assay, the authors tested
these 29 compounds in three additional HDmodels—PC12 cells, yeast, and C. elegans, four of
them (R1, R2, R3, and R4) being active in all these models, and two of them also active in a HD
rat brain slice assay. Although their mechanism of action is still under study, these compounds
seem to specifically target mutant HTT toxicity across cell-, tissue-, and organism-based HD
models.
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3. Mutant Protein Clearance/Degradation Assays
A different strategy than those referred above is to perform an HTS directed at the cellular
degradation of mutant polyQ proteins. With the purpose of identifying compounds promoting
the clearance of the mutant polyQ protein in mammalian cells, Coufal et al. used the HTT gene
with 103Qs in fusionwith EGFP, placed under inducible control of an ecdysone control element
in PC12 cells.305 These authors screened a library of 37,000 compounds, basing their screen on
fast degradation of the Q130-EGFP fusion proteins 24 hr after the inducer removal. Following
toxicity studies, they identified 31 compounds that accelerated degradation of this protein, of
which two were structurally similar compounds, A28 and A31. A second assay aiming to study
these compounds in terms of their specificity for a mutant (Q79) or a wt (Q23) HTT protein in
PC12 cells showed that A31 increased clearance and cell viability for the mutant HTT but not
for wt protein.305
An HTS screening to search for modulators of autophagy was performed in a Saccha-
romyces cerevisiae model by Sarkar et al.306 The mTOR kinase is a major negative regulator
of autophagy,341 and thus an interesting drug target in protein aggregation-related diseases,
although the utility/safety of its chronic inhibition is under debate. In this HTS, 15,000 com-
pounds were screened and the authors identified 12 novel small-molecule enhancers (SMERs)
of autophagy, modulating the levels of HTT and A35T α-synuclein, and 21 inhibitors of the
cytostatic effects of rapamycin (SMIRs) in yeast. The SMERs were shown to be independent
or functioning downstream of mTOR, and proved to attenuate mutant HTT toxicity in HD
cell and Drosophila models.
Another cell-based assay through a time-resolved FRET analysis was performed by Pa-
ganetti et al., the main advantage of which was the possibility to adapt the design for protein
visualization in intracellular imaging assays, with fixed and permeabilized cells.303 To validate
the system, the authors tested 10,000 compounds for their ability to modulate intracellular
HTT levels, with an additional cytotoxicity readout. In this manner, by screening a natural
product library, the authors identified six molecules (trichostatin A analogue, staurosporine,
anisomycin, cycloheximide, borrelidin and BAY 61–3606) that efficiently reduced or increased
the mutant HTT present in the cells.
Lately, an HTS using a hippocampal HN10 cell line expressing mutant HTT and time-
resolved FRET assay, identified several hits, including Hsp90 inhibitors.304 These compounds
strikingly decreased mutant HTT levels without major toxic effects. The hit NVP-AUY922
was shown to enhance the mutant protein degradation also in HdhQ150 embryonic stem
(ES) cells and ES cell-derived neurons. This compound significantly decreased the soluble full-
length mutant HTT levels and enhanced mutant HTT clearance without induction of Hsp70,
suggesting it is acting through a mechanism other than chaperone induction and making it a
promising therapeutic molecule.
Recently, Costa et al. used a cell-based system for HTS and tested a library of compounds
with the goal of reducing the levels of mutant ATXN3; after this primary screening, the authors
performed a secondary screening using organotypic brain slice cultures froma transgenicmouse
model of MJD/SCA3 (YACMJD84.2).101 From 1,250 FDA-approved drugs, it was found that
the atypical antipsychotic drug aripiprazole reduces the levels of mutant ATXN3 in both
systems. This compound was further tested in vivo in the mouse and fly models of MJD/SCA3
increasing the longevity of the flies and reducing mutant ATXN3 species in the brain of the
transgenic mouse model.307
4. Transcription Dysregulation Assays
As the knowledge of the pathogenic mechanisms of polyQ diseases evolves, more relevant
and quantifiable readouts can be used for HTS’s of compounds. Although the transcription
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dysregulation of polyQ diseases is still not understood at the mechanistic level, this seems
to be an important aspect of their pathogenesis. In this line, it is known that mutant HTT
is able to sequester the CREB co-activator CBP through direct polyQ interactions leading
to reduced CREB-mediating transcription.342 Taking this into consideration, a recent study
from Lazzeroni et al. described a novel phenotypic screening assay to identify modulators
of huntingtin-induced transcriptional dysregulation.310 The authors used a stable cell line
expressing an inducible full-length mutant HTT gene (138Q), together with a reporter gene
under the control of the cAMP responsive element (CRE), known to be perturbed by expanded
polyQ. The full-length protein used in this study enabled a more disease-relevant cellular
phenotype than thatmeasured formodels expressing exon-1or otherHTT fragments, previously
described. As a proof-of-concept, upon treatment with Rho kinase inhibitor Y27632, one
cellular clone showed reversible inhibition of HTT reporter activity and was then used for a
HTS of 24,000 compounds; 64 of these compounds were identified to have different specificity
levels for CRE-mediated transcriptional regulation, and secondary assays were performed to
tackle their mechanisms of action and their effects on mutant HTT aggregation.
Recent studies have also been focusing on other parameters of polyQ pathogenesis and
on candidate targets. One is the activation of the HSF-1, which has been shown to restore
proteostasis in a wide range of neurodegenerative diseases.129,136,139,309 A few small molecules
were already identified as regulators of protein conformation through the activation of HSF-1
in HeLa cell308 and yeast-based assays.309 In spite of being a transcription factor-based assay,
this study also has aggregation as a therapeutic target.
5. Whole Organism Based Screens
Although the majority of the HTS’s are performed in a simple cell-based assays and the in
vivo studies in rodent models are only used as a last part of the screening, before testing the
compounds in clinical trials, some nonrodent in vivo models can actually be used for primary
library screenings. Despite their higher cost and throughput limitations when compared to
assays described above, D. melanogaster and C. elegans are two models that can be used for
drug screenings, with the advantage of being multicellular organisms and displaying polyQ
disease-related quantifiable phenotypes for HTS. PolyQ-associated phenotypes, as motor im-
pairment, for instance, could be used as first line readouts in Drosophila311 and C. elegans
models141,313 in the future of polyQ HTS’s. One of the major concerns of in vitro and cell-based
assays is whether the hits will be also effective (and not toxic) in a whole animal model. In this
context, C. elegans is a powerful model for drug testing in whole animal context, due to its
short life cycle, small size, and easy culturing in liquid medium. Several neurobiological and
antiparasitic drug studies in C. elegans also provide a strong basis to use this organism in drug
discovery identification.343,344 Voisine et al. used a C. elegans model of polyQ neurotoxicity
expressing N-terminal 171 aa fragment of human HTT with 151Qs in neurons, and mimicking
the degeneration and cell death (ASH sensorial neurons) of the human disease, dependent on
both age and the length of the polyQ tract.312 The authors tested nine candidate compounds
previously identified in cell cultures and animal studies in the C. elegans model and found that
two FDA-approved compounds, LiCl and mithramycin, independently and in combination,
alleviated HD neurotoxicity.312 Due to its easiest genetic manipulation, C. elegans is also valu-
able to study the drugs’ mechanisms of action by turning on/off possible targets, accelerating
drug discovery for polyQ diseases. A neuronal dysfunction-based screen of FDA compounds in
C. elegans model of MJD/SCA3 was recently described, in which 48 effective molecules were
identified, including the selective serotonin re-uptake inhibitor—citalopram. This compound
was highly effective in the rescue of locomotion impairment and also in the decrease of ATXN-3
aggregation. Following studies in a mouse model of MJD/SCA3 with citalopram also showed
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an improvement in the locomotor impairment and a decrease in ATXN-3 aggregation, together
with other neuroprotective effects.313
C. Considerations on Drug Discovery Strategies in PolyQ Diseases
In the last decade, a significant number of HTS assays have been established that lead to
the identification of multiple of polyQ disease-modifying compounds, comprising both FDA-
approved drugs and novel chemically synthesized or natural molecules. A further challenge is
to test these molecules in clinical trials and use them as tools to enhance the understanding of
the polyQ disease mechanisms, therefore unravelling novel therapeutical targets.
The hurdles for the novel molecules identified in large-scale screenings can be complex, as
they need to pass several filters, including their analysis in different secondary assays in terms of
toxicity, potency, metabolic stability, adequate pharmacokinetic profile, and, relevant to polyQ
diseases, their capability to cross the blood–brain barrier (BBB).
In this perspective, the best candidates will be the FDA-approved compounds known to
cross the BBB, which, once they prove to be effective in animal models, can be taken to clinical
trials quite fast without lengthy safety studies—the re-purposing approach.345–348
A unifying handicap in polyQ disease therapeutics discovery is that mutant polyQ ex-
pression is associated with the disturbance of several cellular mechanisms. The multiplicity of
affected pathways makes the process of drug discovery difficult since it may be hard to define
the most important disease mechanism to target. However, the challenging but also productive
pathway that has been travelled so far in this field, together with the fast technological evolution
improvement in biotechnology, means that we will have the best tools to tackle the emerging
and old questions, hopefully toward a significant advance in the development of therapeutic
strategies for these devastating diseases.
Both approaches presented in this review (candidate-based and unbiased drug screenings)
have their pros and cons in the discovery of new promising compounds for polyQ disorders.
To date, it seems that more successful compounds were identified with candidate-based ap-
proaches since that was the primarily used strategy along the years. Yet, and despite being
more expensive due to high technology requirements, unbiased drug screenings are gaining
relevance, and already allowed the identification of promising compounds for which validation
should be pursued in preclinical trials. These compounds may lead us to very relevant novel
targets and may help to elucidate more precisely the mechanisms involved in the course of the
disease.
However, a challenge still needs to be addressed for both strategies: results must be repli-
cated in more than once in different models of a given disease. In this perspective, it is also
intriguing that a large number of positive preclinical results published in the last years for polyQ
diseases were not pursued and, more importantly, did not advance to Clinical Trials (see Sec-
tion 3), which suggests a requirement for more rigorous studies with robust validation strategies
but also more investment and effort in the establishment of drug discovery and development
pipelines for these rare disorders.
3. OVERVIEW OF CLINICAL TRIALS IN POLYQ DISEASES
Clinical trials are an essential step in the discovery of new treatments and provide the final
evidence of a molecule’s efficacy, contributing for the advancing of medical knowledge and
patient care. Despite the enormous efforts in the past decades, there is no effective treatment
for polyQ diseases. However, several clinical trials were performed and numerous are ongoing.
In some of these, specific symptoms of these diseases could be attenuated (chorea, alertness,
or palliative benefits).272,349–360 The majority of the clinical trials published to date in polyQ
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diseases are small studies with few patients, mostly open-label, observational and/or retro-
spective trials; hence, there is a clear need for novel well-powered randomized controlled trials
(RCTs). These trials are more quantitative, comparative and controlled experiments in which
the effect of a specific treatment may be determined with less bias. Randomization is also
considered a powerful aspect of the experimental design reducing allocation bias and enabling
the detection of the differences in outcome only attributable to the intervention. Table III
summarizes the double-blinded, phase 2 and/or phase 3 randomized controlled clinical trials
completed to date for polyQ diseases, with 20 or more patients, available at clinicaltrials.gov
and/or Pubmed (excluding open-label and retrospective trials). The main objective of this
categorization was to cover the high-quality evidence RCTs.
Intriguingly, in the polyQ field very few of the clinical trials performed to date were based
on in vivo preclinical data. Most compounds were chosen based on positive effects and safety
of each specific drug in another disease or for other indication rather than on preclinical
studies. A few of these, for instance, antihistamine, antidepressants, or cannabinoid agonists,
did lead to partial improvements (see Table III). However, some examples of a progression from
preclinical to clinical trials do exist. Watase et al. showed an improvement of neurological and
pathological phenotypes in a knock-in mouse model of SCA1 when treated with lithium.210
Thereafter, the same compoundwas tested in SCA1 (NCT00683943) and SCA2375,377; however,
with only few or not relevant positive outcomes. Curiously, lithium carbonate was tested in
MJD/SCA3 patients with only limited effects 377 on SARA scores and on disease progression;
and only after this human clinical trial a study in a mouse model ofMJD/SCA3 was published,
with no positive results.211 Another example was VPA, which was previously described to
alleviate neurodegeneration in a Drosophilamodel of MJD/SCA3,252 although with only mild
phenotypic improvement in an MJD/SCA3 mouse model.254 When administered to patients,
VPA led to an improvement in locomotor function given by the decrease in global SARA
score255; however, several methodological issues, namely, the very low number of patients in
each group and the secondary effects observed, including dizziness and loss of appetite, should
be taken into consideration in the interpretation of these results.255
In the case of HD, 10 out of 21 compounds tested were based on preclinical data, mainly
in mouse and C. elegans. For example, fluoxetine, a common antidepressant, was shown to
improve hippocampal-dependent cognitive and depressive-like behaviors in HD mice, as well
as to rescue neurogenesis deficits and volume loss in the dentate gyrus of these mice.379 In
contrast, the clinical trials showed no overall effect of fluoxetine in total functional capacity
(TFC) and in standardized neurological, cognitive, and behavioral ratings.365 Duration and
age at initiation of treatment might, however, have been a limiting factor in this (and other)
trials. Another example is the case of creatine, which showed positive effects in several models
of HD, both at the behavioral and molecular levels.228,229 In spite of the controversy regarding
clinical trials in HD patients, oral creatine administration was shown to increase the serum and
brain levels of creatine as well as decrease the serum levels of 8OH2’dG, an indicator of DNA
oxidative damage known to be markedly increased in HD patients.380 Recently, an RCT in HD
patients using creatine showed a slower cortical and striatal atrophy progression at 6 and 18
months of followup.232
For SBMA, one of two compounds studied in patients to date was tested in a mouse model
of the disease. Leuprorelin showed promising results in an SBMA mouse model, reversing the
behavioral and histopathological phenotypes.381 However, when administered to patients, this
compound did not show significant effects.373
Overall and despite many clinical trials performed, unfortunately none of the compounds
tested to date proved to be the ideal candidate. These findings alert for the importance of
gathering more preclinical data in the appropriate models in order to support the decision of
a human clinical trial with candidate compounds. Issues also exist with rigor in preclinical
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trials and with adequacy of models; extensive validation of findings by different labs and in
more than one model may be demanded in the future to increase the probability of success in
humans. Additionally, the correct study design and statistical measures should be used, as well
as the right dosages, for each animal model so that results can be more rigorously translated to
patients.
The vast majority of the clinical trials in polyQ diseases have been performed for HD, as
depicted in Table III, which is the most common of these disorders. However, in the case of
positive outcomes, some of the compounds may provide good candidates to test in other polyQ
diseases. Nevertheless, the design and success of polyQ clinical trials constitute a challenge
due to the particularities of these diseases, namely, the following: (i) highly variable clinical
presentation and slow progression of symptoms; (ii) lack of reliable and specific targetable
biomarkers; (iii) small number of patients; and (iv) high costs of clinical trials in relation to
the investment for rare diseases. In fact, as mentioned above, the majority of clinical trials
performed up to now have failed or produced slight success. Therefore, it is crucial to critically
analyze the results obtained so far, so that we are able to design improved trials in the future
and increase the likelihood of success. Some issues regarding patient risks and side effects,
study duration, end-point sensitivity, availability of biomarkers of the disease(s), sample size,
trial rationale and preclinical study results, pharmacological and methodology questions, and
clinical trial design could underlie the current overall lack of positive results. On the other hand,
despite the considerable advances regarding our knowledge of the genetics and pathophysiology
of polyQ diseases in the past decade, the field is still lacking relevant biomarkers of the disease
onset and progression, which must be also validated during RCTs along with clinical outcomes.
Improving the reliability and validity of performance measures of the composite rating scales,
neuroimaging studies and/or blood-based transcriptomic studies are major investments that
should bemade in the field, even though theymay only bear results in themedium term. Finally,
a more effective approach to early phase clinical trials is required to speed up the identification
of suitable drugs for these diseases.
While no overall effective treatment for polyQ diseases is available, physical and/or pallia-
tive therapies to maintain the individual’s independence in all environmental contexts should
be implemented for as long as possible. The working goal of this kind of therapy is to es-
tablish strategies to optimize sensorial information, to improve cognition through different
activities, enhance communication, increase the quality and control of movement in different
body postures, improve approaches for an independent gait, exercise against resistance, and
improve hypotonia and motor control and speech therapy.382–385 There is also a need for these
approaches to be studied using RCT experimental designs, and perhaps their synergistic effect
with the above-mentioned candidate drugs should also be explored. In fact, in a very good
example of such a study, Miyai et al. reported short-term evident beneficial effects of intensive
rehabilitation in patients with degenerative cerebellar disease.386 Even small steps may repre-
sent a great help and motivation leading to an improvement and sustainable quality of life for
patients with polyQ diseases and their families.
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